# Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

> **NCT00519259** · PHASE1 · UNKNOWN · sponsor: **National Institute on Drug Abuse (NIDA)** · enrollment: 12 (—)

## Conditions studied

- Methamphetamine Dependence

## Interventions

- **DRUG:** Lobeline

## Key facts

- **NCT ID:** NCT00519259
- **Lead sponsor:** National Institute on Drug Abuse (NIDA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 12 (—)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519259, "Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00519259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*